OBJECTIVES. An increasing number of oseltamivir-resistance associated mutations (H275Y in the neuraminidase NA gene) are being reported in H1N1/2009 viruses isolated from patients treated with oseltamivir, particularly in the immunocompromised. It is important to identify the presence of these drug resistance-associated mutations to optimize the care for such patients.

METHODOLOGY. A rapid and cost-effective High Resolution Melting (HRM) PCR assay was developed for this purpose using an unlabeled probe to screen for the H275Y mutation among patients treated with oseltamivir, especially the highly susceptible immunocompromised patients. Isolated probe PCR (IP-PCR) was performed using Superscript III Platinum One-step qRT-PCR kit (Invitrogen) on either the LightScanner LS32 (Idaho) or the LightCycler LC v2.0 (Roche) system, both of which utilize the uniquely designed LC glass capillaries as reaction receptacles. To initiate the IP-PCR, 2 µL of extracted viral RNA was added to 6 µL of reaction mix containing optimized amounts of forward and reverse primers. A calculated excess amount of forward primer and unlabelled probe mix (2 µL) was then aliquotted into the upper well of the capillary tube, without being spun down with the reaction mix. A calculated excess amount of forward primer and unlabelled probe mix (2 µL) was then aliquotted into the upper well of the capillary tube, without being spun down with the reaction mix. Upon completion of the IP-PCR, the 8 µL reaction mix was mixed with the pre-deposited primer/probe mix by inversion and reverse-spinning, followed by an extended 15-cycle asymmetric amplification reaction and continuous HRM data acquisition. The in vitro synthesized RNA transcripts for both wildtype and mutant were diluted using pooled negative RNA extracts and used as the standard calibrator. The lower limit of detection (LLOD) and lower limit of quantification (LLOQ) for the mutant strain were determined.

RESULTS. The melt peaks for the unlabeled probe with a mismatched base C (wildtype) and that with a perfectly matched base T (mutant) were clearly discernable at 65.5°C and 69.25°C (Figure 1), respectively. The assay reproducibly amplified concentrations of 20 to 2x10^7 RNA copies/reaction, thus giving an LLOD of 20 copies/reaction. The LLOQ, defined as the lowest concentration whereby the difference of 3.33 Ct value per log is maintained, was 200 copies/reaction (Figure 2). Good resolution of the melt peaks was obtained for the whole series of 0-100% mixed-mutant/wildtype standards (Figure 1).

CONCLUSION. This assay is able to provide easily discernable results for qualitative and quantitative detection of WT (H275)/mutant (Y275) mixes. The preliminary results suggest that this assay and platform may accurately identify H275Y populations down to 10% of the viral population, though further validation on clinical specimens is required.

REFERENCES & ACKNOWLEDGEMENTS
This project was funded by the NUHS Interdepartment project fund NPRCO10/NH05O, awarded to Julian Tang Wei-Tze, Paul A. Tambyah and Evelyn S. Koay.